Climb Bio (CLYM) EPS (Weighted Average and Diluted) (2021 - 2026)
Climb Bio (CLYM) reported EPS (Weighted Average and Diluted) of -$0.2 for Q1 2026, up 35.48% on a YoY basis from -$0.15 in Q1 2025, and up 20.0% quarter-over-quarter from -$0.25 in Q4 2025.
Climb Bio (CLYM) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Climb Bio has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.2 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 35.48% year-over-year to -$0.2; the trailing twelve-month figure through Mar 2026 stood at -$0.77 (up 65.16% YoY), and the FY2025 full-year result was -$0.88, up 42.48% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.2, up from -$0.25 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.04 in Q4 2024, with the low at -$1.81 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.35 across 5 years, with a median of -$0.2 in 2026.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 130.77% in 2024 against a maximum downside of 852.63% in 2024.
- Climb Bio's EPS (Weighted Average and Diluted) stood at -$0.29 in 2022, then surged by 55.17% to -$0.13 in 2023, then jumped by 130.77% to $0.04 in 2024, then plunged by 725.0% to -$0.25 in 2025, then increased by 20.0% to -$0.2 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.2 (Q1 2026), -$0.25 (Q4 2025), and -$0.19 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Climb Bio | 774.84 Mn | 774.84 Mn | - | -0.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.20 |
| Dec 31, 2025 | -0.25 |
| Sep 30, 2025 | -0.19 |
| Jun 30, 2025 | -0.13 |
| Mar 31, 2025 | -0.31 |
| Dec 31, 2024 | 0.04 |
| Sep 30, 2024 | -0.13 |
| Jun 30, 2024 | -1.81 |
| Mar 31, 2024 | -0.06 |
| Dec 31, 2023 | -0.13 |
| Sep 30, 2023 | -0.15 |
| Jun 30, 2023 | -0.19 |
| Mar 31, 2023 | -0.84 |
| Dec 31, 2022 | -0.29 |
| Sep 30, 2022 | -0.37 |
| Jun 30, 2022 | -0.37 |
| Mar 31, 2022 | -0.50 |
| Dec 31, 2021 | 1.25 |
| Sep 30, 2021 | -0.70 |
| Jun 30, 2021 | -3.11 |